Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Anteris Technologies ( (AU:AVR) ) has issued an announcement.
Anteris Technologies has received FDA approval to begin the PARADIGM Trial, a global clinical study evaluating the safety and effectiveness of its DurAVR® Transcatheter Heart Valve (THV) in patients with severe calcific aortic stenosis. This trial, which will enroll approximately 1000 patients across the United States, Europe, and Canada, represents a significant step forward for Anteris in advancing its life-saving technology and aims to support a future Premarket Approval submission in the U.S., potentially enhancing its position in the structural heart device market.
The most recent analyst rating on (AU:AVR) stock is a Buy with a A$10.00 price target. To see the full list of analyst forecasts on Anteris Technologies stock, see the AU:AVR Stock Forecast page.
More about Anteris Technologies
Anteris Technologies Global Corp. is a global structural heart company focused on designing, developing, and commercializing advanced medical devices to restore healthy heart function. Based in Australia with a significant presence in Minneapolis, USA, Anteris specializes in innovative solutions for structural heart disease, with its lead product being the DurAVR® Transcatheter Heart Valve (THV), designed to treat aortic stenosis using biomimetic technology and patented anti-calcification tissue.
Average Trading Volume: 18,241
Technical Sentiment Signal: Sell
See more data about AVR stock on TipRanks’ Stock Analysis page.